Live and recent posts from across the Fediverse tagged #excessivedaytimesleepiness, aggregated by home.social.
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?
Viatris Inc. (NASDAQ:VTRS) announced on September 16 that Japan’s Ministry of Health, Labour and Welfare approved WAKIX, or…
#EuropeSays #Japan #JP #airwayobstruction #excessivedaytimesleepiness #Nihon #Viatris #ViatrisInc.
https://www.europesays.com/japan/94799/
Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy
Japan’s Ministry of Health, Labour and Welfare has approved Viatris’ Wakix (pitolisant) for excessive daytime sleepiness (EDS) related…
#EuropeSays #Japan #JP #approval #excessivedaytimesleepiness #Japanese #narcolepsy #obstructivesleepapnoea #OSAS #PhilippeMartin #Viatris #WAKIX
https://www.europesays.com/japan/93141/
Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy
Japan’s Ministry of Health, Labour and Welfare has approved Viatris’ Wakix (pitolisant) for excessive daytime sleepiness (EDS) related…
#EuropeSays #Japan #JP #approval #excessivedaytimesleepiness #Japanese #narcolepsy #obstructivesleepapnoea #OSAS #Viatris #WAKIX
https://www.europesays.com/japan/92977/
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
Approval Addresses High Unmet Medical Need and Further Advances Viatris’ Innovative Portfolio in Japan PITTSBURGH, Sept. 16, 2026…
#EuropeSays #Japan #JP #controlledsubstance #excessivedaytimesleepiness #globalhealthcarecompany #narcolepsy #OSAS #patients #treatmentoption #Viatris #WAKIX
https://www.europesays.com/japan/92567/
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
Takeda has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Orzeyful (oveporexton) to treat…
#EuropeSays #Japan #JP #excessivedaytimesleepiness #MHLW #narcolepsy #Nihon #Orzeyful #Takeda
https://www.europesays.com/japan/79956/
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
Takeda has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Orzeyful (oveporexton) to treat…
#EuropeSays #Japan #JP #excessivedaytimesleepiness #MHLW #narcolepsy #Orzeyful #Takeda
https://www.europesays.com/japan/79940/
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1 https://www.byteseu.com/2306201/ #ExcessiveDaytimeSleepiness #Japan #MHLW #narcolepsy #Orzeyful #Takeda
https://www.europesays.com/uk/1156270/ Lupin gets USFDA nod for generic tablets to treat excessive daytime sleepiness #ExcessiveDaytimeSleepiness #GenericTablets #HarmonyBiosciences #Health #lupin #LupinLtd #Medication #Pitolisant #UK #UnitedKingdom #USFoodAndDrugAdministration #USFDA
Lupin gets USFDA nod for generic tablets to treat excessive daytime sleepiness
New Delhi: Pharma major Lupin Ltd on Monday said it has received final approval from the US health…
#NewsBeep #News #Medication #AU #Australia #excessivedaytimesleepiness #generictablets #HarmonyBiosciences #Health #Lupin #LUPINLTD #Pitolisant #usfoodanddrugadministration #USFDA
https://www.newsbeep.com/au/859942/
https://www.europesays.com/ie/643503/ Lupin gets USFDA nod for generic tablets to treat excessive daytime sleepiness #Éire #ExcessiveDaytimeSleepiness #GenericTablets #HarmonyBiosciences #Health #IE #Ireland #Lupin #LupinLtd #Medication #Pitolisant #USFoodAndDrugAdministration #USFDA
https://www.europesays.com/ie/480374/ Why Long Daytime Naps May Signal Health Risks #DaytimeNappingAndHealth #EffectsOfFrequentNapping #Éire #ExcessiveDaytimeSleepiness #Health #HealthCare #Healthcare #HealthyNappingForOlderAdults #IE #Ireland #MorningNapsMortalityRisk #NapLengthAndLongevity #SleepHealthForOlderAdults
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region https://www.byteseu.com/1454406/ #AsiaPacificRegion #ExcessiveDaytimeSleepiness #GlobalHealthcareCompany #InnovativeProducts #Japan #OSAS #Pharma #RegulatoryApproval #StatusEpilepticus #Viatris
https://www.alojapan.com/1392924/viatris-completes-acquisition-of-aculys-pharma-including-exclusive-rights-to-pitolisant-in-japan-and-to-spydia-in-japan-and-certain-other-markets-in-the-asia-pacific-region/ Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region #AsiaPacificRegion #ExcessiveDaytimeSleepiness #GlobalHealthcareCompany #InnovativeProducts #Japan #JapanNews #news #OSAS #pharma #RegulatoryApproval #StatusEpilepticus #Viatris Strengthens Viatris’ Presence in Japan With the Addition of Two Innovative Assets Targeting Ar
Interesting interview with Dr. Quinn Eastman regarding his new book on #hypersomnia.
#ExcessiveDaytimeSleepiness
https://youtu.be/pKD6oliTCyw